Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li and Lizheng Shi ()
Additional contact information
Dongzhe Hong: Tulane University
Lei Si: University of New South Wales
Minghuan Jiang: Xi’an Jiaotong University
Hui Shao: Tulane University
Wai-kit Ming: Sun Yat-sen University
Yingnan Zhao: Xavier University of Louisiana
Yan Li: The New York Academy of Medicine
Lizheng Shi: Tulane University

PharmacoEconomics, 2019, vol. 37, issue 12, No 11, 1553-1553

Abstract: CORE diabetes model was used throughout the article for consistency.

Date: 2019
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-019-00833-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:37:y:2019:i:12:d:10.1007_s40273-019-00833-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-019-00833-1

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().